MassIVEapplication/xmlftp://massive-ftp.ucsd.edu/v06/MSV000092953/primaryOK2000000Heeyoun Hwanghttps://massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=d19492dd7ee14a69baee8897ae9e7a45heeyounh@kbsi.re.krMassIVE65UNIMOD:35 - "Oxidation or Hydroxylation."ProteomicsOrbitrap Fusion LumosHomo Sapiens (ncbitaxon:9606)Korea Basic Science InstituteCell., 5430407P10Rik, AU067770, C10orf47, proteomic analysisPlasma Membranes, Activity, 5430407P10Rik, Laboratory, Heterograft, Feature, protein, TRANSPL HETEROL, Tumor, Prolin, Technic, Pancreatic Neoplasm, Protoplasm, 2-Amino-3-hydroxypropionic acid, protein polypeptide chains, Techniques, Ca tail of pancreas, Ca head of pancreas, Immunogold-Silver Techniques, Roles, Immunogold-Silver Technique, L-Proline, CG9063, Line, Alleviating interaction, Concepts, establishment and maintenance of substrate location, Research Activity, protein aggregate, Laboratory Research, Survival Times, Priorities, AU018434, Prognoses, 2410003B13Rik, P, Tissue, hypoplasia, proteins, Pancreatic Cancers, BcDNA:GH03694, (2S)-pyrrolidine-2-carboxylic acid, PROLINE, inner endospore membrane, plasma membrane lipid bilayer, Immunogold-Silver Technic, Xenotransplantations, 2-amino-3-hydroxypropanoic acid, AU067770, malignant neoplasm, plasmalemma, Role Concepts, Immunolabeling Technique, Plasma Membrane, xenotransplant, stage, Malignancies, Research Priority, Pancreatic Acinar Carcinomas, Immunogold Technics, DmelCG9063, pancreatic tumour, pancreas neoplasm, C10orf47, single organism signaling, Tumors, establishment and maintenance of substance location, Carcinoma, SOK1, Tfar15, DL-Proline, Cytoplasms, Mean Survival, malignant neoplasm of body of pancreas, familial, Immunogold Technique, Research Priorities, Immunogold, Immunogold Techniques, cellular membrane, single organism localization, ductal adenocarcinoma of the pancreas, juxtamembrane, Benign, Immunolabeling Technic, Role Concept, 3-Hydroxyalanine, Immunolabeling Technics, Role, pancreatic duct cancer, pancreatic carcinoma, Technics, bacterial inner membrane, Pancreatic, sok1, Cancer of the Pancreas, 1500019J11Rik, Heterologous Transplantations, Tfa15, Lines, Research and Development, Carcinomas, Xenograft, pancreatic duct adenocarcinoma, absence, Xenotransplantation, Factors, Cancer of Pancreas, cell membrane, Time, Transplantation, prolinum, malignant neoplasm of head of pancreas, Prognostic, BcDNAGH03694, Benign Neoplasms, Immunogold Silver Techniques, TFAR15, Xenografts, (-)-proline, Features, (S)-pyrrolidine-2-carboxylic acid, Pancreas, 3L6, Pancreatic Acinar Carcinoma, Malignant Neoplasms, Activities, metastatic, Patient, Ca body of pancreas, rich, L Serine, PNCA, L-Serine, other neoplasm, L-pyrrolidine-2-carboxylic acid, Acinar Carcinomas, establishment and maintenance of cellular component location, Prognostic Factor, Immunogold-Silver, (-)-(S)-proline, L-alpha-pyrrolidinecarboxylic acid, Neoplasms, developmental stage, Cytoplasmic Membrane, Benign Neoplasm, Pancreas Cancer, Gene, Prognostic Factors, pancreas, protein-containing complex, Transplantations, Malignant, Pancreas Cancers, heterologous transplantation, Rate, Survival Rate, polypeptide chain, reduced, Pancreatic Cancer, Survival, pyrrolidine-2-carboxylic acid, Gene Products, establishment and maintenance of position, PDAC, Pancreatic Acinar, tiny, Technique, Immunogold Silver Technics, Pancreatic Carcinomas, study, pancreas tubular adenocarcinoma, Hpro, pattern, Malignancy, Research, distribution, Pancreatic Carcinoma, Acinar Carcinoma, absent from organism, 2-Pyrrolidinecarboxylic acid, Heterografts, suppressive genetic interaction (sensu inequality), Mean Survival Times, Cytoplasmic, Neoplasias, Cumulative, (S)-2-pyrrolidinecarboxylic acid, pancreatic ductal carcinoma, C10orf47., Cytoplasmic Membranes, Clients, L Proline, C86992, Characteristics, Development and Research, (S)-2-carboxypyrrolidine, Ste20-like, integral to plasma membrane, Heterologous, Cancer, small, Malignant Neoplasm, Immunogold Technic, Survival Rates, Cumulative Survival Rate, prolina, protein complex, integral component of plasma membrane, pancreatic ductal adenocarcinoma, pancreatic neoplasm, Proteins, Cell Lines, Immunohistocytochemistry, Factor, function, Client, Pancreas Neoplasm, Cell, ductal adenocarcinoma of pancreas, pancreas ductal adenocarcinoma, Concept, Mean Survival Time, Serin, Cumulative Survival Rates, Priority, Characteristic, MT, XENOTRANSPL, native protein, natural protein, Protein, Research Activities, proteomic analysis, Neoplasm, proline, establishment and maintenance of localization, Cumulative Survival, Cell Membranes, Data Base, Immunolabeling, Mean, Plasma, Rates, malignant neoplasm of tail of pancreas, Membranes, Survival Time, pancreatic tumor, primary cancer, Immunocytochemistry, (-)-2-pyrrolidinecarboxylic acid, YSK1, L-Prolin, underdeveloped, Ysk1, malignant neoplasm of duct of Wirsung, HETEROL TRANSPL, patient, Cancers, single-organism localization, Membrane, malignant tumor, Protein Gene Products, Gene Proteins, localisation, signalling process, pancreatic tubular adenocarcinoma, Protoplasms, Immunogold-Silver Technics, Immunolabeling Techniques, Times, L-(-)-proline, cytoplasmic membrane, ysk1, Ccm3, CCM3, Pancreas Neoplasms, sok-1, Neoplasia0PXD045646falseProteomic analysis of PROSER2 overexpressing cellsPancreatic Ductal Adenocarcinoma (PDAC) is diagnosed at an advanced stage in around 70% of patients and has a dismal 5-year survival rate of less than 11%. This dismal prognosis arises not only due to the absence of diagnostic markers and molecular targets but also due to its aggressive metastatic characteristics. In this research, we took a departure from conventional proteomic studies to identify new molecular targets for pancreatic cancer. We chose uPE1 from an extensive pancreatic cancer proteomic research database and focused our investigation on Proline and Serine Rich 2 (PROSER2), a protein that ranked high in both the cell membrane and cytoplasm. While PROSER2 has been reported to be associated with tumor progression, its exact function remained unclear. In our study using cell lines and patient-derived cells, PROSER2 exhibited a higher expression pattern primarily in cells derived from primary tumors compared to those from metastatic tissues. Overexpression of PROSER2 significantly reduced the metastatic ability of cancer cells, whereas its suppression had the opposite effect. Through proteomic analysis, we discovered that PROSER2 interacts with STK25 and PDCD10, proteins associated with cancer metastatic signaling, and this interaction was confirmed in PROSER2-overexpressing MIAPACA-2 cells. Immunocytochemistry in patient-derived xenograft (PDOX) cells further verified the co-localization of endogenous PROSER2 with STK25 and PDCD10 in the cell membrane and cytoplasm. Taken together, this study is the first to describe the novel role of PROSER2 in antagonizing invasion and proliferation.MSV000092953